glp·helper
glphelper.com/mounjaro/oklahoma/oklahoma-city
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Oklahoma City, OK

Verified Mounjaro providers in Oklahoma City, OK. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Mounjaro weight loss →trial-anchored estimate
city providers
34
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Oklahoma
34 of 34 shown

Find a Mounjaro provider in Oklahoma.

Every entry is checked against the NPI registry and the Oklahoma medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Oklahoma city · /mounjaro/oklahoma/{city}
§ 03Getting Mounjaro in Oklahoma City
34 providers · Oklahoma City, OK

How to get Mounjaro in Oklahoma City.

34 GLP-1 prescribers and 7 local resource types are on record for Oklahoma City, plus 2 nearby towns in the directory.

Prescribers in Oklahoma City
34 prescribers
34 GLP-1 prescribers in Oklahoma City, most listed as Family Medicine (16), Internal Medicine, Endocrinology, Diabetes & Metabolism (13) and Internal Medicine (5). Any Oklahoma-licensed physician, nurse practitioner, or PA can prescribe Mounjaro, over video or in person. The nearest towns on record are Norman (29 providers) and Tulsa (34 providers).
Around the prescription in Oklahoma City
7 listed nearby
6 dietitians, 3 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 5 places to move are on record near Oklahoma City.
Medicaid (weight loss)
Diabetes only
As of April 2026, Oklahoma Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Oklahoma’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Oklahoma

Diagnosed diabetes reaches 11.3% of adults in Oklahoma.

of Oklahoma adults have obesity
36.8%
diagnosed diabetes
11.3%

Age-adjusted estimates for Oklahoma, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight losshow tirzepatide titration works
§ 05Support around Mounjaro in Oklahoma City
6 gyms

The prescription is one part. Here is the rest, in Oklahoma City.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Oklahoma City, OK, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Colaw Fitness of Oklahoma City Gyms
GYM
4.9 on Google · 13117 reviews
3645 NW 39th St
Website
10GYM
GYM
4.6 on Google · 1703 reviews
1020 SW 104th St
Website
VASA Fitness
GYM
4.4 on Google · 1532 reviews
4106 S Western Ave
Website
10GYM
GYM
4.7 on Google · 1531 reviews
711 S Air Depot Blvd
Website
Planet Fitness
GYM
4.4 on Google · 1048 reviews
4202 Northwest Expy
Website
Planet Fitness
GYM
4.5 on Google · 1007 reviews
5701 E Reno Ave # B
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Marese Abdul Kaleem, RD/LD
RD
Registered dietitian
2301 Nw 122Nd St
Call 405-413-8227NPI 1962182725
Rayna Allen, RDN, LD, MCN
RD
Registered dietitian
1200 Childrens Ave
Call 580-334-9171NPI 1053068668
Rebecca Allen, RD/LD
RD
Registered dietitian
1200 Childrens Ave Ste 4500
Call 405-271-6764NPI 1548412380
Naomi Ard, RD/LD
RD
Registered dietitian
921 Ne 13Th St
Call 405-270-0501NPI 1174614671
Stephanie Atkinson, CDE, RD/LD, MS
RD
Registered dietitian
4140 W Memorial Rd Ste 321
Call 405-748-4726NPI 1841552742
Ryan Baggett, RD
RD
Registered dietitian · Sports Dietetics
301 Nw 132Nd St
Call 405-905-9228NPI 1841996600
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Mounjaro cash price (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Mounjaro providers in Oklahoma

NPI-verified Mounjaro (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Mounjaro in other states

Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in Oklahoma

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]